Deutsch English Français

Contact

EP2252689

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2252689

EP2252689 - USE OF ANTI-CONNEXIN POLYNUCLEOTIDES FOR THE TREATMENT OF SURGICAL ADHESIONS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 27.04.2018 Database last updated on 14.05.2024
Former	Grant of patent is intended Status updated on 30.07.2017
Former	Examination is in progress Status updated on 28.11.2016
Most recent event Tooltip	27.04.2018	Application deemed to be withdrawn	published on 30.05.2018 [2018/22]
Applicant(s)	For all designated states Ocunexus Therapeutics, Inc. 12481 High Bluff Drive, Suite 150 San Diego, CA 92130 / US
	[2018/01]
Former [2017/52]	For all designated states Ocunexus Therapeutics, Inc. 12520 High Bluff Drive, Suite 350 San Diego, CA 92130 / US
Former [2013/50]	For all designated states Coda Therapeutics, Inc. 12520 High Bluff Drive Suite 350 San Diego CA 92130 / US
Former [2010/47]	For all designated states Coda Therapeutics, Inc. 10505 Sorrento Valley Road, Suite 395 San Diego, CA 92121 / US
Inventor(s)	01 / BECKER, David, L. 19 Lapwing Way Abbots Langley Hertfordshire WD5 OGG / GB
	02 / GREEN, Colin, R. 3/4 Crescent Road 1023 Epson Auckland / NL
	03 / DUFT, Bradford, J. P.o. Box 1133 Rancho Santa Fe CA 92067 / US
	[N/P]
Former [2010/47]	01 / BECKER, David, L. 19 Lapwing Way Abbots Langley Hertfordshire WD5 OGG / GB
	02 / GREEN, Colin, R. 3/4 Crescent Road NL-1023 Epson Auckland / NL
	03 / DUFT, Bradford, J. P.o. Box 1133 Rancho Santa Fe CA 92067 / US
Representative(s)	J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB
	[N/P]
Former [2010/47]	Tuxworth, Pamela M. J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB
Application number, filing date	08866069.1	22.12.2008
	[2010/47]
	WO2008US14024
Priority number, date	US20070008748P	21.12.2007 Original published format: US 8748 P
	[2010/47]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2009085273
	Date:	09.07.2009
	Language:	EN
	[2009/28]
	Type:	A2 Application without search report
	No.:	EP2252689
	Date:	24.11.2010
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 09.07.2009 takes the place of the publication of the European patent application.
	[2010/47]
Search report(s)	International search report - published on:	EP	01.10.2009
Classification	IPC:	A61L31/04, A61L31/14, A61K9/00, A61K47/10, A61K47/16, C12N15/11, C12N15/113	[2017/30]
	CPC:	C12N15/1138 (EP,US); A61K47/10 (EP,US); A61K47/12 (EP,US); A61K47/16 (EP,US); A61K47/186 (EP,US); A61K47/36 (EP,US); (+) A61K47/38 (EP,US); A61K9/0014 (EP,US); A61K9/06 (EP,US); A61K9/7007 (EP,US); A61L31/042 (EP,US); A61L31/145 (EP,US); A61P17/00 (EP); A61P41/00 (EP); A61P43/00 (EP); A01K2207/05 (EP,US); A01K2207/30 (EP,US); A01K2227/10 (EP,US); A01K2227/105 (EP,US); A01K2227/107 (EP,US); A01K2267/03 (EP,US); C12N2310/11 (EP,US) (-)
	Former IPC [2010/47]	C12N15/11
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2010/47]
Title	German:	VERWENDUNG VON ANTI-CONNEXIN-POLYNUKLEOTIDEN ZUR BEHANDLUNG CHIRURGISCHER ADHÄSIONEN	[2010/47]
	English:	USE OF ANTI-CONNEXIN POLYNUCLEOTIDES FOR THE TREATMENT OF SURGICAL ADHESIONS	[2010/47]
	French:	UTILISATION DE POLYNUCLÉOTIDES ANTI-CONNEXINE POUR LE TRAITEMENT D'ADHÉRENCES POST-CHIRURGICALES	[2010/47]
Entry into regional phase	21.07.2010	National basic fee paid
	21.07.2010	Designation fee(s) paid
	21.07.2010	Examination fee paid
Examination procedure	21.07.2010	Amendment by applicant (claims and/or description)
	21.07.2010	Examination requested [2010/47]
	18.09.2012	Despatch of a communication from the examining division (Time limit: M06)
	12.07.2013	Reply to a communication from the examining division
	05.05.2014	Cancellation of oral proceeding that was planned for 08.05.2014
	08.05.2014	Date of oral proceedings (cancelled)
	15.07.2014	Despatch of communication that the application is refused, reason: substantive examination {1}
	22.06.2015	Despatch of a communication from the examining division (Time limit: M06)
	08.04.2016	Reply to a communication from the examining division
	26.07.2016	Despatch of a communication from the examining division (Time limit: M06)
	12.05.2017	Reply to a communication from the examining division
	31.07.2017	Communication of intention to grant the patent
	12.12.2017	Application deemed to be withdrawn, date of legal effect [2018/22]
	16.01.2018	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2018/22]
Appeal following examination	12.09.2014	Appeal received No. T0177/15
	25.11.2014	Statement of grounds filed
	07.04.2015	Result of appeal procedure: continuation of examination procedure
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 18.09.2012
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	12.05.2017	Request for further processing filed
	12.05.2017	Full payment received (date of receipt of payment) Request granted
	24.05.2017	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the examination report
	08.04.2016	Request for further processing filed
	08.04.2016	Full payment received (date of receipt of payment) Request granted
	29.04.2016	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the examination report
	12.07.2013	Request for further processing filed
	12.07.2013	Full payment received (date of receipt of payment) Request granted
	26.07.2013	Decision despatched
Fees paid	Renewal fee
	24.12.2010	Renewal fee patent year 03
	28.12.2011	Renewal fee patent year 04
	11.12.2012	Renewal fee patent year 05
	12.12.2013	Renewal fee patent year 06
	11.12.2014	Renewal fee patent year 07
	10.12.2015	Renewal fee patent year 08
	13.12.2016	Renewal fee patent year 09
	12.12.2017	Renewal fee patent year 10
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[E]WO2009075882 (CODA THERAPEUTICS INC [US], et al) [E] 1-52 * see claims and Seq.1-12 *;
		[XY]WO2006134494 (CODA THERAPEUTICS LTD [NZ], et al) [X] 33-45 * see claims * [Y] 1-52;
		[XY]WO0044409 (UNIV LONDON [GB], et al) [X] 33-45 * see claims * [Y] 1-52;
		[XY] - QIU C ET AL, "Targeting Connexin43 Expression Accelerates the Rate of Wound Repair", CURRENT BIOLOGY, CURRENT SCIENCE, GB, (20030930), vol. 13, no. 19, ISSN 0960-9822, pages 1697 - 1703, XP004545249 [X] 33-45 * abstract * [Y] 1-52 DOI: http://dx.doi.org/10.1016/j.cub.2003.09.007
		[XY] - MORI RYOICHI ET AL, "Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, (20061201), vol. 119, no. 24, ISSN 0021-9533, pages 5193 - 5203, XP002529576 [X] 33-45 * the whole document * [Y] 1-52 DOI: http://dx.doi.org/10.1242/jcs.03320
	Examination	- LIU YANCHIN ET AL, "Crosslinked hyaluronan hydrogels containing mitomycin C reduce postoperative abdominal adhesions", FERTILITY AND STERILITY, (200504), vol. 83, doi:doi:10.1016/j.fertnstert.2004.09.038, ISSN 0015-0282, pages 1275 - 1283, XP005162787 DOI: http://dx.doi.org/10.1016/j.fertnstert.2004.09.038

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p